MARKET

TMDX

TMDX

Transmedics Group
NASDAQ
69.07
+2.94
+4.45%
After Hours: 70.00 +0.93 +1.35% 18:26 01/27 EST
OPEN
66.13
PREV CLOSE
66.13
HIGH
69.09
LOW
66.02
VOLUME
305.48K
TURNOVER
0
52 WEEK HIGH
69.09
52 WEEK LOW
10.00
MARKET CAP
2.21B
P/E (TTM)
-46.3122
1D
5D
1M
3M
1Y
5Y
Insider Sell: Transmedics Group
Insider Sell: Transmedics Group
MT Newswires · 3d ago
Healthcare Outlook 2023
Seeking Alpha · 5d ago
Jim Cramer Praises Unilever, But Says 'It's Not Going To Run Overnight'
Benzinga · 01/19 14:16
Morgan Stanley Sticks to Their Hold Rating for TransMedics Group (TMDX)
TipRanks · 01/06 16:26
--Morgan Stanley Adjusts TransMedics Group's Price Target to $63 From $54, Keeps Equalweight Rating
--Morgan Stanley Adjusts TransMedics Group's Price Target to $63 From $54, Keeps Equalweight Rating
MT Newswires · 01/06 11:56
--Morgan Stanley Adjusts TransMedics Group Price Target to $63 From $54, Maintains Equal Weight Rating
--Morgan Stanley Adjusts TransMedics Group Price Target to $63 From $54, Maintains Equal Weight Rating
MT Newswires · 01/06 11:24
This Stock Jumped 183% This Year and Could Keep on Rising in 2023
Tip Ranks · 12/26/2022 14:47
Med-tech companies could make sense for health care investors in 2023 as defensive sector
Seekingalpha · 12/24/2022 21:00
More
About TMDX
TransMedics Group, Inc. is a commercial-stage medical technology company. The Company is focused on developing organ transplant therapy for end-stage organ failure patients across multiple disease states. The Company has designed and developed an organ care system (OCS), a portable organ perfusion, optimization and monitoring system that utilizes its customized technology to replicate near-physiologic conditions for donor organs outside of the human body. It designed its OCS technology platform to perfuse donor organs with warm, oxygenated, nutrient-enriched blood, while maintaining the organs in a living, functioning state. It has developed three OCS products, one each for lung, heart and liver transplantation. Its products include OCS Lung, OCS Heart, and OCS Liver. Its OCS product consists of three components customized for each organ, which include the OCS Console, OCS Perfusion Set and OCS Solutions. It is also developing OCS products for additional organs, including kidneys.

Webull offers kinds of TransMedics Group Inc stock information, including NASDAQ:TMDX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, TMDX stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading TMDX stock methods without spending real money on the virtual paper trading platform.